These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8785995)

  • 1. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
    Wood DJ
    Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
    Levenbook I; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory tests for live attenuated poliovirus vaccines.
    Wood DJ; Macadam AJ
    Biologicals; 1997 Mar; 25(1):3-15. PubMed ID: 9167004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurovirulence.
    Wood D
    Dev Biol Stand; 1999; 101():127-9. PubMed ID: 10566785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of the neurovirulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes.
    Horie H; Tano Y; Doi Y; Hashizume S
    Biologicals; 1998 Dec; 26(4):289-97. PubMed ID: 10403032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBER: new approaches to biological product testing.
    Donlon JA
    Dev Biol Stand; 1999; 101():21-5. PubMed ID: 10566770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of experiments in poliovirus-susceptible transgenic mice for evaluating current potency tests of inactivated polio vaccine (IPV).
    Taffs R; Dragunsky E; Nomura T; Hioki K; Levenbook I; Fitzgerald E
    Dev Biol Stand; 1996; 86():345. PubMed ID: 8785985
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
    Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
    Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.
    Abe S; Ota Y; Koike S; Kurata T; Horie H; Nomura T; Hashizume S; Nomoto A
    Virology; 1995 Feb; 206(2):1075-83. PubMed ID: 7856082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
    Dragunsky E; Nomura T; Karpinski K; Furesz J; Wood DJ; Pervikov Y; Abe S; Kurata T; Vanloocke O; Karganova G; Taffs R; Heath A; Ivshina A; Levenbook I
    Bull World Health Organ; 2003; 81(4):251-60. PubMed ID: 12764491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.
    Mento SJ; Weeks-Levy C; Tatem JM; Gorgacz EJ; Waterfield WF
    Dev Biol Stand; 1993; 78():93-9; discussion 99-100. PubMed ID: 8388835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence.
    Chumakov K; Norwood L; Parker M; Dragunsky E; Taffs R; Ran Y; Ridge J; Levenbook I
    Dev Biol Stand; 1993; 78():79-89; discussion 88-9. PubMed ID: 8388834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the new control methods for oral poliomyelitis vaccine.
    Grachev VP; Karganova GG; Rumyantsev AA; Ivanova OE; Eremeeva TP; Drozdov SG
    Dev Biol (Basel); 2001; 105():211-7. PubMed ID: 11763330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence.
    Chumakov KM; Norwood LP; Parker ML; Dragunsky EM; Ran YX; Levenbook IS
    J Virol; 1992 Feb; 66(2):966-70. PubMed ID: 1309923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.
    Rezapkin GV; Chumakov KM; Lu Z; Ran Y; Dragunsky EM; Levenbook IS
    Virology; 1994 Jul; 202(1):370-8. PubMed ID: 8009849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine.
    Dragunsky E; Taffs R; Chernokhvostova Y; Nomura T; Hioki K; Gardner D; Norwood L; Levenbook I
    Biologicals; 1996 Jun; 24(2):77-86. PubMed ID: 8889053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.